David Ricks, Eli Lilly CEO (Photographer: Al Drago/Bloomberg via Getty Images)
October 12, 2023 11:09 AM EDTUpdated October 13, 09:36 AM
R&D

Eli Lil­ly touts PhI­II mirik­izum­ab win in Crohn’s de­spite woes in oth­er con­di­tions

Lei Lei Wu

News Reporter

Eli Lil­ly said its an­ti-in­flam­ma­to­ry med­i­cine mirik­izum­ab helped about half of peo­ple with Crohn’s dis­ease en­ter re­mis­sion af­ter one year in a Phase III study …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times